Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Carboplatin and Paclitaxel in Advanced NSCLC
NCT00768131Phase 2Withdrawn
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2008
- Primary completion
- Oct 2008
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of KL-140 in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Planned start Oct 2008; status: withdrawn.
02
Drugs
KL-140
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00768131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00768131.